Clinical trial NCT00316732: Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
Official title: Observational Sutdy to Assess the Effectiveness of Avodart in Subjects With Benign Prostatic Hyperplasia in Day to Day Clinical Practice
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostatic Hyperplasia
Keywords: Avodart
IPSS
BPH
dutasteride
EQ-5D
Observational
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2006-04-21
Enrollment: 173
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.


Eligibility criteria: Inclusion Criteria:

* Patients who not have received any pharmacological treatment or surgical interventions for BPH (Benign Prostatic Hyperplasia).
* Patients should be prescribed dutasteride in compliance with the UK SmPC and BAUS guidelines on the treatment of BPH.
* Patients must only enter the study after the decision to prescribe dutasteride has been undertaken.

Exclusion criteria: None specified

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Exeter
country: United Kingdom
facility: GSK Investigational Site
state: Devon
city: Plymouth
country: United Kingdom
facility: GSK Investigational Site
state: Devon
city: Colchester
country: United Kingdom
facility: GSK Investigational Site
state: Essex
city: Stevenage
country: United Kingdom
facility: GSK Investigational Site
state: Hertfordshire
city: Manchester
country: United Kingdom
facility: GSK Investigational Site
state: Lancashire
city: Manchester
country: United Kingdom
facility: GSK Investigational Site
state: Lancashire
city: Leicester
country: United Kingdom
facility: GSK Investigational Site
state: Leicestershire
city: Leytonstone
country: United Kingdom
facility: GSK Investigational Site
state: London
city: Enfield
country: United Kingdom
facility: GSK Investigational Site
state: Middlesex
city: Nottingham
country: United Kingdom
facility: GSK Investigational Site
state: Nottinghamshire
city: Tauton
country: United Kingdom
facility: GSK Investigational Site
state: Somerset
city: Sunderland
country: United Kingdom
facility: GSK Investigational Site
state: Tyne & Wear
city: Sutton Coldfield
country: United Kingdom
facility: GSK Investigational Site
state: West Midlands
city: Birmingham
country: United Kingdom
facility: GSK Investigational Site
city: Bradford
country: United Kingdom
facility: GSK Investigational Site
city: Bradford
country: United Kingdom
facility: GSK Investigational Site
city: Bristol
country: United Kingdom
facility: GSK Investigational Site
city: East Kilbride
country: United Kingdom
facility: GSK Investigational Site
city: Hull
country: United Kingdom
facility: GSK Investigational Site
city: Ilkeston, Derbyshire
country: United Kingdom
facility: GSK Investigational Site
city: Leeds
country: United Kingdom
facility: GSK Investigational Site
city: London
country: United Kingdom
facility: GSK Investigational Site
city: London
country: United Kingdom
facility: GSK Investigational Site
city: London
country: United Kingdom
facility: GSK Investigational Site
city: Sheffield
country: United Kingdom
facility: GSK Investigational Site
city: Torquay
country: United Kingdom
facility: GSK Investigational Site
city: Wakefield
country: United Kingdom
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: